Syngenic

City of Hope to Present New Research at the American Association of Cancer Research (AACR) Annual Meeting 2024, Highlighting Promising Data on Prostate, Colorectal and Pancreatic Cancer

Retrieved on: 
Tuesday, March 12, 2024
Research, Other Health, General Health, Pharmaceutical, Oncology, Biometrics, Hospitals, Genetics, Health Technology, Science, Biotechnology, Health, Other Science, Breast cancer, Syngenic, Convergent, Computational biology, Patient, Distinguishing, Beckman Research Institute, City, Tumor microenvironment, PSCA, Haematopoietic system, Memory, AACR, Lymphocyte, Treatment, Convergent Science, Neoplasm, Road, Systems biology, CRC, Division, Microbiome, Hematology, Pharmaceutical industry

To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.

Key Points: 
  • To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.
  • They found that the model was sensitive to microbiome modulation and that the use of patient-derived human fecal matter transfers can significantly impact PSCA-CAR T cell directed anti-tumor responses.
  • , will also chair the inaugural AACR event called From Cancer Discoveries to Patients on April 4 and 5.
  • The event brings together leaders in clinical research, biotech and the investment community as part of AACR’s commitment to expediting the advancement of lifesaving cancer discoveries.

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Retrieved on: 
Tuesday, February 20, 2024
Senior, Docetaxel, TSX, Growth, Treatment, Frontiers, Triple-negative breast cancer, Immunity, TNBC, Volume, Patient, PDC, Survival, Syngenic, Research, Cancer, Vaccine

Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor (SORT1) and expedites the internalization and delivery of the cytotoxic payload (docetaxel) directly into cancer cells.

Key Points: 
  • Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor (SORT1) and expedites the internalization and delivery of the cytotoxic payload (docetaxel) directly into cancer cells.
  • The article, “Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing” appears in the “Cancer Immunity and Immunotherapy” section of the February (Volume 15) issue of the journal.
  • Additionally, combining sudocetaxel zendusortide with an anti-PD-L1 checkpoint inhibitor led to increases in tumor growth inhibition and median animal survival.
  • This realization supports the rationale for further exploration of the combination of sudocetaxel zendusortide with immunotherapy.”

ChemPartner Unveils Highly Anticipated Biology Database

Retrieved on: 
Friday, December 22, 2023
Biology, Database, Drug discovery, Collection, Drug development, Data analysis, Research, PDX, Literature, Statistics, Biochemistry, CDX, Gene expression, CNS, Genomics, Gene, Pathology, Syngenic, SOC, Mining, Pharmacology, Medical imaging

SHANGHAI, Dec 23, 2023 - (ACN Newswire) - ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database.

Key Points: 
  • SHANGHAI, Dec 23, 2023 - (ACN Newswire) - ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database.
  • The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.
  • To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages.
  • The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database.

FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma

Retrieved on: 
Friday, November 10, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Brain, NYSE, Hepatocellular carcinoma, Food, Prevalence, Carcinoma, ODD, Glioblastoma, Patient, Enrollment, Death, BBB, Syngenic, Lung cancer, SCLC, MD, Cancer, Growth, HCC, NSCLC, Pharmaceutical industry, Medical imaging

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, announced today that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to its lead asset THIO, a cancer telomere-targeting agent, for the treatment of glioblastoma.

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, announced today that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to its lead asset THIO, a cancer telomere-targeting agent, for the treatment of glioblastoma.
  • This is the third orphan drug designation granted to THIO, following the receipt of orphan drug designations for hepatocellular carcinoma (HCC) and small cell lung cancer (SCLC) in 2022.
  • “We are pleased to receive a third orphan drug designation for THIO, further highlighting FDA’s recognition of THIO’s potential in the treatment of multiple cancer indications, including rare ones such as glioblastoma,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer.
  • “Each year, globally, more than 300,000 people are diagnosed with brain tumors, of which, 25,000 are in the United States.

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
ACT, Molecule, Survival, ET, Plasma, Half-life, Therapy, Biomarker, Renal cell carcinoma, CD19, Pembrolizumab, TM, PD-1, IL-2, Immunity, Neoplasm, Poster, CD8, Pharmacokinetics, Mouse, SITC, Immunotherapy, Syngenic, Webcast, Abstract, Annual general meeting, Flow cytometry, Tumor microenvironment, Lung cancer, Safety, Society, Cancer, Patient, Human, Therapeutic index, Toxicity, Vaccine, Pharmaceutical industry

Additional posters representing an expansive body of data demonstrating the potential of Werewolf’s PREDATOR™ platform and INDUKINE™ product candidates will also be presented.

Key Points: 
  • Additional posters representing an expansive body of data demonstrating the potential of Werewolf’s PREDATOR™ platform and INDUKINE™ product candidates will also be presented.
  • Additional posters with preclinical data supporting the PREDATOR platform and INDUKINE product candidates will also be presented at the meeting.
  • These data will provide early insight into the profile of WTX-124 and preferential activation through our INDUKINE design, including additional data since the abstract submission in June,” said Randi Isaacs, M.D., Chief Medical Officer of Werewolf.
  • Pharmacokinetic data as of June 22, 2023, demonstrated WTX-124 sustained prodrug exposure in plasma with low levels of active IL-2.

MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO

Retrieved on: 
Monday, October 30, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, NSCLC, NYSE, Lung cancer, Colorectal cancer, Syngenic, Prodrug, Immunity, Cancer, Chemistry, Patient, DNA, Vaccine, Pharmaceutical industry, Speaker

MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced positive results from an investigational new drug-enabling study of the Company’s second-generation telomere-targeting agents derived from lipid-modified THIO molecules.

Key Points: 
  • MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced positive results from an investigational new drug-enabling study of the Company’s second-generation telomere-targeting agents derived from lipid-modified THIO molecules.
  • MAIA’s second-generation telomere-targeting molecule program seeks to discover new compounds with improved specificity towards cancer cells relative to normal cells, potentially increased anticancer activity, and stronger chemistry manufacturing control characteristics.
  • The new THIO prodrugs are lipid conjugated compounds derived from THIO.
  • The telomere-centric action of MAIA’s lead candidate THIO is being evaluated in Phase 2 clinical trials (THIO-101) in non-small-cell lung carcinoma (NSCLC) patients.

Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Retrieved on: 
Tuesday, October 3, 2023
Stimulator of interferon genes, Bifunctional, AACR, Biskit, Syngenic, Survival, Immunotherapy, MDNA, CD8, Synergism, TSX, Neoplasm, Poster, PD-1, IL-2R, Conference, Pharmaceutical industry, Vaccine

TORONTO and HOUSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy), were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 - 4, 2023, in Toronto, Canada.

Key Points: 
  • TORONTO and HOUSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy), were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 - 4, 2023, in Toronto, Canada.
  • “We believe that our dual-functioning BiSKIT candidates, such as MDNA223, are more potent and selective and may have an increased capacity to induce superior CD8+ T cell responses against tumor cells.
  • The sum of encouraging preclinical data on MDNA223 highlights the potential of Medicenna’s BiSKIT platform to broadly delivery effective therapy to otherwise challenging-to-treat ‘cold’ tumors.
  • Copies of the poster will be posted to the “ Events and Presentations ” page of Medicenna’s website following the conclusion of the meeting.

Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services (BioMice) From Antibody Drug R&D

Retrieved on: 
Thursday, August 31, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Homologous recombination, Graft-versus-host disease, CRISPR, DNA, Radiation, Obesity, Asthma, Accreditation, PD, Therapy, NASH, Diabetes, Chronic kidney disease, CDX, IBD, HER2, Syngenic, Gene editing, Pathology, SPF, Atopic dermatitis, Multimedia, SLE, CD3E, CCR8, Atherosclerosis, Medication, PDX, MS, Psoriasis, Fibrosis, Service provider, HKEX, AAALAC, Immune system, Mouse, Cytokine, PD-1, ESC, B cell, Pharmacology, Rheumatoid arthritis, Fine chemical, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio.
  • With the company’s expanding initiatives focused on antibody drug development, the company has officially established two business divisions, with one focusing on animal models and preclinical services, and the other focusing on the discovery and development of novel antibody-based drugs for out-licensing and partnerships.
  • View the full release here: https://www.businesswire.com/news/home/20230831376847/en/
    Biocytogen’s preclinical platforms include custom gene-editing services, generation of off-the-shelf humanized and/or immunodeficient animal and cell model products, and preclinical pharmacology services.
  • To better showcase these business lines, and to enhance the brand image of the company’s preclinical models and services, the company will integrate these major platforms under the “BioMice™” sub-brand.

Biocytogen Establishes Two Business Divisions To Distinguish Preclinical Models and Services (BioMice) from Antibody Drug R&D

Retrieved on: 
Thursday, August 31, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, Homologous recombination, Graft-versus-host disease, CRISPR, DNA, Radiation, Obesity, Asthma, Accreditation, PD, Therapy, NASH, Diabetes, Chronic kidney disease, CDX, IBD, HER2, Syngenic, Gene editing, Pathology, SPF, Atopic dermatitis, Multimedia, SLE, CD3E, CCR8, Atherosclerosis, Medication, PDX, MS, Psoriasis, Fibrosis, Service provider, HKEX, AAALAC, Immune system, Mouse, Cytokine, PD-1, ESC, B cell, Pharmacology, Rheumatoid arthritis, Fine chemical, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio.
  • With the company’s expanding initiatives focused on antibody drug development, the company has officially established two business divisions, with one focusing on animal models and preclinical services, and the other focusing on the discovery and development of novel antibody-based drugs for out-licensing and partnerships.
  • View the full release here: https://www.businesswire.com/news/home/20230830517505/en/
    Biocytogen’s preclinical platforms include custom gene-editing services, generation of off-the-shelf humanized and/or immunodeficient animal and cell model products, and preclinical pharmacology services.
  • To better showcase these business lines, and to enhance the brand image of the company’s preclinical models and services, the company will integrate these major platforms under the “BioMice™” sub-brand.

Kernal Biologics to Present at 3rd Annual mRNA-Based Therapeutics Summit

Retrieved on: 
Thursday, July 20, 2023
Syngenic, Survival rate, Cancer, Quality of life, Research and development, LNP, Therapy, Patient, Safety, Vaccine, Pharmaceutical industry

CAMBRIDGE, Mass., July 20, 2023 /PRNewswire/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced it is presenting in person at the 3rd Annual mRNA-Based Therapeutics Summit in Boston, MA.

Key Points: 
  • Preclinical Data Support Use of Onco-selective mRNA LNPs as a Novel, Promising Modality for Immuno-oncology Applications
    CAMBRIDGE, Mass., July 20, 2023 /PRNewswire/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced it is presenting in person at the 3rd Annual mRNA-Based Therapeutics Summit in Boston, MA.
  • "We have been investing in our computational platform to design onco-selective mRNAs.
  • Additionally, Mr. Yusuf Erkul, M.D., Co-founder and CEO of Kernal Bio, will moderate both morning and afternoon Translation sessions on Friday, July 28.
  • Details for the Kernal Bio presentation are as follows: